February 13, 2018 / 1:22 PM / 3 months ago

BRIEF-Catabasis Reports Edasalonexent Preserved Muscle Function And Substantially Slowed Duchenne Muscular Dystrophy Disease Progression

Feb 13 (Reuters) - Catabasis Pharmaceuticals Inc:

* CATABASIS PHARMACEUTICALS REPORTS EDASALONEXENT PRESERVED MUSCLE FUNCTION AND SUBSTANTIALLY SLOWED DUCHENNE MUSCULAR DYSTROPHY DISEASE PROGRESSION THROUGH MORE THAN ONE YEAR OF TREATMENT

* CATABASIS - PLANS TO INITIATE SINGLE GLOBAL PHASE 3 TRIAL WITH EDASALONEXENT IN PATIENTS WITH DMD REGARDLESS OF MUTATION TYPE IN FIRST HALF OF 2018

* CATABASIS PHARMACEUTICALS - ‍EDASALONEXENT CONTINUED TO BE WELL TOLERATED WITH NO SAFETY SIGNALS OBSERVED IN TRIAL​

* CATABASIS PHARMACEUTICALS INC - TOP-LINE RESULTS IN SINGLE GLOBAL PHASE 3 TRIAL WITH EDASALONEXENT IN PATIENTS EXPECTED IN 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below